Goldline Pharmaceutical IPO: Goldline Pharmaceutical new IPO is all set for investment, with a book build issue of ₹11.61 crore. The company is going to issue 0.27 crore new shares through this public offer (IPO). If you want to invest in it, the subscription window will open from May 12, 2026 and will close on May 14, 2026. The allotment of shares is expected to be finalized by May 15, after which it can be listed on the BSE SME platform on May 19, 2026.
Goldline Pharmaceutical IPO Overview
Talking about investment terms, the company has fixed the price band of ₹41 to ₹43 per share. It will be mandatory for retail investors to purchase a minimum lot of 3,000 shares, with a minimum investment amount of ₹2,58,000 as per the upper price. Whereas for HNI category, a minimum of 3 lots (9,000 shares) will have to be secured, which will require ₹3,87,000. The entire issue is being managed by ‘Cumulative Capital Private Limited’ as the lead manager, while ‘BigShare Services’ is its registrar. Investors are advised to read the DRHP documents of the company carefully for detailed information.
| Details | Descriptions |
|---|---|
| IPO Date | 12 to 14 May, 2026 |
| Listing Date | Tue, May 19, 2026 |
| Face Value | ₹10 per share |
| Issue Price Band | ₹41 to ₹43 |
| Lot Size | 3,000 Shares |
| Sale Type | Fresh Capital only |
| Total Issue Size | 27,00,000 shares (agg. up to ₹12 Cr) |
| Reserved for Market Maker | 1,38,000 shares (agg. up to ₹0.5934 Cr) |
| Fresh Issue (Ex Market Maker) | 25,62,000 shares (agg. up to ₹11 Cr) |
| Net Offered to Public | 25,62,000 shares (agg. up to ₹11 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE SME |
| Share Holding Pre Issue | 69,00,000 shares |
| Share Holding Post Issue | 96,00,000 shares |
Goldline Pharmaceutical IPO Schedule
| Details | Description |
|---|---|
| IPO Open Date | Tue, May 12, 2026 |
| IPO Close Date | Thu, May 14, 2026 |
| Tentative Allotment | Fri, May 15, 2026 |
| Initiation of Refunds | Mon, May 18, 2026 |
| Credit of Shares to Demat | Mon, May 18, 2026 |
| Tentative Listing Date | Tue, May 19, 2026 |
Goldline Pharmaceutical IPO Lot Size Details
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 2 | 6,000 | ₹2,58,000 |
| Individual investors (Retail) (Max) | 2 | 6,000 | ₹2,58,000 |
| S-HNI (Min) | 3 | 9,000 | ₹3,87,000 |
| S-HNI (Max) | 7 | 21,000 | ₹9,03,000 |
| B-HNI (Min) | 8 | 24,000 | ₹10,32,000 |
Overview of Goldline Pharmaceutical
Goldline Pharmaceutical Limited: A new definition of excellence in healthcare
Goldline Pharmaceuticals is a reputed name in the Indian pharmaceutical industry, active in marketing high quality pharmaceutical products under the brand name “Goldline”. The main objective of the company is to bridge the gap between modern medical practices and the needs of patients.
Goldline has divided its product range into five distinct categories, to provide precise solutions in every area of medicine:
- Goldline Pharma: This category includes a total of 42 products. This segment mainly caters to the needs of physicians, orthopedics, ENT, chest specialist, general and specialty surgery, gastroenterology, neurology and urology.
- Goldline Cardinal: This segment focuses on specialist therapies with 54 products. Its benefits are mainly available to diabetologists, endocrinologists, cardiologists and general physicians.
- Goldline Ayushman: This range dedicated to children’s health has 18 products, specially designed for pediatricians and neonatologists.
- Goldline InLife: This range includes 22 products for serious health conditions. This segment provides its services to Intensivists, Critical Care Consultants and Super Specialty Surgeons.
- Goldline Wellness: Supportive care is extremely important in cancer treatment. The 10 products in this range are specially designed to improve the quality of life of patients and provide support during treatment.
Our business model and operations
Goldline Pharmaceuticals operates on an asset-light business model. The company does not manufacture drugs itself, but instead partners with third-party manufacturers based on market research and their own specific quality standards. This ensures that each product conforms to government regulations and quality standards.
Currently, the company is working with a strong network of 15 manufacturing partners and 7 major distributors. Our products are widely available in states like Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan and Bihar. Apart from this, we also provide full support to hospitals and healthcare providers in procurement and material supply.
Key Strengths of Goldline Pharmaceutical (Competitive Strengths)
Some of our key features as a successful pharmaceutical company differentiate us from others in the market:
- Experienced Leadership: Our promoters and management team have deep industry knowledge and an excellent track record of success.
- Agile Business Model: Our ‘asset-light’ model allows us to adapt quickly to changing market needs and offer competitive products.
- Expansion possibilities: The structure of the company is such that it can be easily expanded with the growth of the business.
- Diverse Product Range: We have a wide and diverse range of products for every type of medical specialty.
- Strong Relationships: We have trusted and long-term relationships with our suppliers, vendors and manufacturers.
- Strong Distribution Network: Our distribution infrastructure is so strong that we ensure timely supply of medicines to remote areas.
Company Financials
Goldline Pharmaceutical Financial Information (Restated Standalone)
For the financial year ending March 31, 2025, Goldline Pharmaceutical Ltd. reported a 19% growth in revenue and a substantial 57% increase in profit after tax (PAT) compared to the previous year.
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 26.28 | 22.93 | 19.39 |
| Total Income | 28.06 | 23.57 | 19.85 |
| Profit After Tax | 2.83 | 1.81 | 0.26 |
| EBITDA | 5.83 | 4.30 | 2.19 |
| Net Worth | 10.35 | 7.87 | 5.89 |
| Reserves and Surplus | 1.65 | 3.76 | 2.08 |
| Total Borrowing | 11.03 | 11.13 | 10.83 |
Key Performance Indicator (KPI)
The market cap. of Goldline Pharmaceutical IPO is ₹ To be declared in Crores.
KPI as of Mar 31, 2025
| KPI | Mar 31, 2025 |
|---|---|
| ROE | 35.84% |
| ROCE | 38.46% |
| Debt/Equity | 1.50 |
| RoNW | 27.38% |
| PAT Margin | 10.10% |
| EBITDA Margin | 20.79% |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS Rs | – | – |
| P/E (x) | – | – |
| Promoter Holding | 79.70% | -% |
Goldline Pharmaceutical IPO Objectives
| Objects of the Issue | Expected Amount (₹ in cr.) |
|---|---|
| Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company | 8.90 |
| General corporate purposes | – |
| Total | 8.90 |
Goldline Pharmaceutical IPO Contact Details
- Goldline Pharmaceutical Ltd.
- 103, F-1, Leela Apartment, Shilpa HSG Society,
- Near Saptagiri Nagar, Shanidham,
- Narendra Nagar,
- Nagpur, Maharashtra, 440015
- +91 712 2786666
- info@goldlinepharma.in
- Website: http://www.goldlinepharma.in
Goldline Pharmaceutical IPO Registrar
Bigshare Services Pvt.Ltd.
| Details | Descriptions |
|---|---|
| Phone: | +91-22-6263 8200 |
| Email: | ipo@bigshareonline.com |
| Website: | https://ipo.bigshareonline.com/IPO_Status.html |
Goldline Pharmaceutical IPO FAQs
When Goldline Pharmaceutical IPO become available?
The IPO will open on Tue, May 12, 2026.
What is the minimum lot size for the Goldline Pharmaceutical IPO?
The minimum lot size is 3,000 shares.
When will the shares for the Goldline Pharmaceutical IPO be allotted?
The allotment is expected to be finalized on Fri, May 15, 2026.
What is the expected listing date for the Goldline Pharmaceutical IPO?
The tentative listing date is Tue, May 19, 2026.
How can I apply for the Goldline Pharmaceutical IPO?
You can apply online through your bank or a broker using either the UPI or ASBA payment methods.
Read also – Property Share Investment Trust-Propshare Celestia SM REIT Details
